newsWith antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research…
9 August 2023 | By Catherine Eckford (European Pharmaceutical Review)
With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research shows Daiichi Sankyo, Seagen and Roche are currently three of the market's most important players.